This study incorporates real-world evidence (RWE) in a value-based budget impact model (BIM) to demonstrate the value and affordability of Gla-300 for the treatment of adult patients with type 2 diabetes mellitus (T2DM) receiving basal insulins (Bis) from a U.S. payer perspective. A prevalence-based modelling approach was employed, consisting of three types of patients receiving BIs: prevalent patients (have been on insulin treatment for at least one year), naïve patients (new to the BI treatment, less than one year), switchers (previously naïve or prevalent patients who have switched insulin treatments). The model assessed the cost of treatment (drug costs), hypoglycemic events (associated with emergency, inpatient, and outpatient visits), and diabetes-related healthcare resource utilization (HCRU) costs (associated with emergency, inpatient, and outpatient visits). The study presented base case results by patient population, type in different scenarios.
Contact us at insights@axtria.com with any questions.